Acurx Pharmaceuticals (ACXP) Competitors $4.31 +0.04 (+0.94%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.34 +0.03 (+0.67%) As of 09/12/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. RLYB, ASBP, ENLV, FBLG, NNVC, ALVR, PASG, NEUP, PMN, and NAIIShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Rallybio (RLYB), Aspire Biopharma (ASBP), Enlivex Therapeutics (ENLV), FibroBiologics (FBLG), NanoViricides (NNVC), AlloVir (ALVR), Passage Bio (PASG), Neuphoria Therapeutics (NEUP), Promis Neurosciences (PMN), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Rallybio Aspire Biopharma Enlivex Therapeutics FibroBiologics NanoViricides AlloVir Passage Bio Neuphoria Therapeutics Promis Neurosciences Natural Alternatives International Acurx Pharmaceuticals (NASDAQ:ACXP) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Is ACXP or RLYB more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Rallybio's return on equity of -71.66% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -436.83% -192.25% Rallybio -5,473.33%-71.66%-65.06% Which has more volatility and risk, ACXP or RLYB? Acurx Pharmaceuticals has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.1, suggesting that its stock price is 210% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ACXP or RLYB? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 8.7% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ACXP or RLYB? In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 2 mentions for Rallybio. Rallybio's average media sentiment score of 1.45 beat Acurx Pharmaceuticals' score of 0.40 indicating that Rallybio is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Neutral Rallybio Positive Which has better valuation and earnings, ACXP or RLYB? Acurx Pharmaceuticals has higher earnings, but lower revenue than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.40Rallybio$640K39.23-$57.78M-$0.94-0.64 Do analysts prefer ACXP or RLYB? Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 619.26%. Rallybio has a consensus price target of $5.00, suggesting a potential upside of 732.22%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Acurx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryRallybio beats Acurx Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.77M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.4021.1774.5225.93Price / SalesN/A480.02549.78198.13Price / CashN/A46.6837.5660.44Price / Book6.849.6112.166.29Net Income-$14.10M-$53.29M$3.28B$270.77M7 Day Performance5.64%0.28%0.87%3.88%1 Month Performance-8.69%5.73%4.96%4.88%1 Year Performance-89.44%10.52%60.74%26.01% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.1595 of 5 stars$4.31+0.9%$31.00+619.3%-89.3%$6.77MN/A-0.403Analyst DowngradeRLYBRallybio3.3909 of 5 stars$0.59-2.4%$5.00+741.6%-45.4%$25.43M$640K-0.6340Positive NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.510.0%N/AN/A$25.35MN/A0.00N/APositive NewsENLVEnlivex Therapeutics2.5407 of 5 stars$1.04-1.9%$10.00+861.5%-32.7%$25.07MN/A-1.7970News CoverageAnalyst ForecastShort Interest ↑FBLGFibroBiologics3.0829 of 5 stars$0.57-0.9%$13.00+2,183.1%-82.8%$24.06MN/A-1.5810News CoverageAnalyst ForecastNNVCNanoViricides0.1536 of 5 stars$1.44-3.4%N/A-13.7%$23.95MN/A-2.0020Short Interest ↑Gap UpALVRAlloVirN/A$4.62-0.9%N/A-75.2%$23.30MN/A-0.23110High Trading VolumePASGPassage Bio3.9345 of 5 stars$7.12-0.8%$75.67+962.9%-53.1%$22.82MN/A-0.39130NEUPNeuphoria Therapeutics2.57 of 5 stars$12.99+9.3%$21.00+61.7%N/A$22.35M$10K0.00N/ANews CoverageAnalyst ForecastPMNPromis Neurosciences3.6746 of 5 stars$0.44+1.6%$4.33+891.6%-64.8%$22.28MN/A-2.085Positive NewsShort Interest ↓NAIINatural Alternatives International1.6423 of 5 stars$3.41-5.3%N/A-44.0%$22.24M$125.48M-2.45290Short Interest ↓High Trading Volume Related Companies and Tools Related Companies Rallybio Alternatives Aspire Biopharma Alternatives Enlivex Therapeutics Alternatives FibroBiologics Alternatives NanoViricides Alternatives AlloVir Alternatives Passage Bio Alternatives Neuphoria Therapeutics Alternatives Promis Neurosciences Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACXP Stock Alerts